PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
91.74%
Some net income increase while TRAW is negative at -44.66%. John Neff would see a short-term edge over the struggling competitor.
-100.00%
Negative yoy D&A while TRAW is 12.64%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
100.00%
Deferred tax of 100.00% while TRAW is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-95.76%
Negative yoy SBC while TRAW is 302.12%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-167.13%
Negative yoy working capital usage while TRAW is 90.90%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-230.77%
Negative yoy AP while TRAW is 90.38%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-79.38%
Negative yoy usage while TRAW is 92.28%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-151.83%
Both negative yoy, with TRAW at -1500.00%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
55.51%
Operating cash flow growth 1.25-1.5x TRAW's 49.68%. Bruce Berkowitz might see better working capital management or consistent margin advantages.
52.86%
Some CapEx rise while TRAW is negative at -91.89%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
52.86%
We have mild expansions while TRAW is negative at -91.89%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.